The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: Long-term follow-up

BJU International

Volumn 109, Issue 1, 2012, Pages 32-39

  Antonarakis, Emmanuel S ^a   Feng, Zhaoyong ^b   Trock, Bruce J ^b   Humphreys, Elizabeth B ^b   Carducci, Michael A ^a   Partin, Alan W ^b   Walsh, Patrick C ^b   Eisenberger, Mario A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

metastasis free survival; natural history; prostate cancer; PSA recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SURVIVAL RATE;

DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 83555166131     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10422.x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term Results. J Urol 2004; 172: 910-4 (Pubitemid 39096421)
3. Freedland SJ, Humphreys EB, Mangold LA, et al,. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9 (Pubitemid 41124175)
4. Moul JW, Bañez LL, Freedland SJ,. Rising PSA in nonmetastatic prostate cancer. Oncology 2007; 21: 1436-45 (Pubitemid 350252938)
5. Sandler HM, Eisenberger MA,. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol 2007; 178: S20-4 (Pubitemid 47211166)
6. Messing EM, Manola J, Yao J, et al,. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9 (Pubitemid 43779173)
7. Tenenholz TC, Shields C, Ramesh VR, Tercilla O, Hagan MP,. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer. Urol Oncol 2007; 25: 101-9 (Pubitemid 46349744)
8. Makarov DV, Humphreys EB, Mangold LA, et al,. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol 2008; 179: 156-61
9. Loblaw DA, Virgo KS, Nam R, et al,. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-605 (Pubitemid 46733088)
10. Abrahamsson PA,. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 49-59
11. Yu EY, Gulati R, Telesca D, et al,. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010; 28: 2668-73
12. Scher HI, Eisenberger M, D'Amico AV, et al,. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22: 537-56 (Pubitemid 41079783)
13. Trock BJ, Han M, Freedland SJ, et al,. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-9 (Pubitemid 351846851)
14. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7 (Pubitemid 29211767)
15. Slovin SF, Wilton AS, Heller G, Scher HI,. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 2005; 11: 8669-73 (Pubitemid 43005915)
16. Okotie OT, Aronson WJ, Wieder JA, et al,. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004; 171: 2260-4 (Pubitemid 38625447)
17. Kalbfleisch JD, Prentice RL,. The Statistical Analysis of Failure Time Data. New York: Wiley, 1980: 14-5
18. Crawford ED, Eisenberger MA, McLeod DG, et al,. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24 (Pubitemid 19211484)
19. Eisenberger MA, Blumenstein BA, Crawford ED, et al,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42 (Pubitemid 28457865)
20. D'Amico AV, Hanks GE,. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993; 72: 2638-43 (Pubitemid 23320225)
21. Patel A, Dorey F, Franklin J, deKernion JB,. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158: 1441-5 (Pubitemid 27391215)
22. Zagars GK, Pollack A,. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997; 44: 213-21 (Pubitemid 27405144)
23. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D,. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20: 4567-73 (Pubitemid 35402960)
24. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH,. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-83 (Pubitemid 37220457)
25. Kim-Sing C, Pickles T, Cohort P,. Outcomes Initiative. Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database. Int J Radiat Oncol Biol Phys 2004; 60: 463-9 (Pubitemid 39233465)
26. Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML,. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc 2007; 82: 422-7 (Pubitemid 46543465)
27. Chang SL, Freedland SJ, Terris MK, et al,. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology 2010; 75: 439-44
28. Hanlon AL, Diratzouian H, Hanks GE,. Post-treatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 297-303 (Pubitemid 34522096)
29. Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A,. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 59-66 (Pubitemid 350251025)
30. Keegan PE, Maththews JNS, Lunec J, Neal DE,. Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int 2000; 85: 392-7 (Pubitemid 30142609)